Abstract
There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Current Vascular Pharmacology
Title: Endothelin-1 and Human Platelets
Volume: 3 Issue: 4
Author(s): I. Anita Jagroop, Stella S. Daskalopoulou and Dimitri P. Mikhailidis
Affiliation:
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Abstract: There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Export Options
About this article
Cite this article as:
Jagroop Anita I., Daskalopoulou S. Stella and Mikhailidis P. Dimitri, Endothelin-1 and Human Platelets, Current Vascular Pharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157016105774329453
DOI https://dx.doi.org/10.2174/157016105774329453 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Plants and Atherosclerosis: A Review on Molecular Aspects
Current Pharmaceutical Design Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Oleocanthal, a Natural anti-Inflammatory Compound in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Editorial: Continuous Positive Airway Pressure: Life-Saving Technology
Current Respiratory Medicine Reviews The Effect of a Common Antibiotics Doxycycline on Non-Healing Chronic Wound
Current Pharmaceutical Biotechnology Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology